<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent studies have demonstrated the feasibility of cytokine gene transfer to enhance the antitumor activities of host immune cells </plain></SENT>
<SENT sid="1" pm="."><plain>Endothelial cells forming the vascular supply of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> may be useful vehicles for the delivery of cytokine molecules in order to effect <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> immunotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>In order to determine whether primary endothelial cells can express cytokine transgenes efficiently, we constructed two retroviral vectors containing a cDNA encoding either recombinant human interleukin-1 alpha (rhIL-1 alpha) or recombinant human interleukin-2 (rhIL-2), called LNCIL-1 alpha and LNCIL-2 respectively, and studied the expression of the two cytokines in vitro in non-immortalized endothelial cells </plain></SENT>
<SENT sid="3" pm="."><plain>Human umbilical vein endothelial cells (HUVEC) transduced with LNCIL-1 alpha or LNCIL-2 secreted 1.8-33 ng/10(6) cells/24 h and 40-246.7 ng/10(6) cells/24 h of biological active rhIL-1 alpha and rhIL-2 respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Mouse microvascular endothelial cells (MMEC) transduced with LNCIL-1 alpha and LNCIL-2 secreted 1.5 ng/10(6) cells/24 h and 5.8-24.7 ng/10(6) of biologically active rhIL-1 alpha and rhIL-2 proteins respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Cocultivation of HUVEC/IL-2 and MMEC/IL-2 with <z:mpath ids='MPATH_458'>normal</z:mpath> human bone marrow cells generated potent cytotoxic activity against K562, Daudi and other cell targets in a <z:chebi fb="0" ids="50076">51Cr</z:chebi>-release assay </plain></SENT>
<SENT sid="6" pm="."><plain>While IL-2 transgene-expressing HUVEC and MMEC retained their <z:mpath ids='MPATH_458'>normal</z:mpath> <z:mp ids='MP_0000002'>morphology</z:mp>, rhIL-1 alpha transgene expression inhibited the growth and altered the <z:mp ids='MP_0000002'>morphology</z:mp> of both HUVEC and MMEC in culture </plain></SENT>
<SENT sid="7" pm="."><plain>The cytokine-gene-transduced endothelial cells retained other endothelial cell features, including uptake of acetylated <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> (Ac-<z:chebi fb="15" ids="39026">LDL</z:chebi>) and expression of <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor, and were euploid as shown by flow cytometry </plain></SENT>
<SENT sid="8" pm="."><plain>These results demonstrate that endothelial cells, by sustaining the production of biologically active rhIL-2 at levels that are sufficient for the activation of potent cytotoxic lymphocyte activity, may be useful agents for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> gene therapy </plain></SENT>
</text></document>